论文部分内容阅读
目的探讨氨溴特罗结合孟鲁司特治疗小儿咳嗽变异性哮喘的临床作用及安全性。方法选取商丘市妇幼保健院2011年2月至2012年12月收治的60例咳嗽变异性哮喘的患儿,根据用药的不同随机分为氨溴特罗组、孟鲁司特组和氨溴特罗联合孟鲁司特组(联合用药组),每组各20例。观察患儿临床疗效和计算不同时间峰值呼气流速(PEF)变异率,以观察肺功能改变情况。结果两种药物单一治疗组患儿咳嗽改善情况无明显差异(P>0.05),发生咳嗽变异性哮喘率较高;但两种药物结合治疗组咳嗽间隔时间明显延长,且发生咳嗽变异性哮喘率明显低于前两组(P<0.05)。结论氨溴特罗联合孟鲁司特治疗小儿咳嗽变异性哮喘可有效改善临床症状,且安全、有效。
Objective To investigate the clinical efficacy and safety of ambroxol combined with montelukast in the treatment of children with cough variant asthma. Methods Sixty children with cough variant asthma admitted from February 2011 to December 2012 in Shangqiu MCH were randomly divided into ambroxol group, montelukast group and amiloride group Luo combined montelukast group (combination group), each group of 20 cases. To observe the clinical efficacy of children and calculate the peak time of peak expiratory flow rate (PEF) mutation rate in order to observe changes in lung function. Results There was no significant difference (P> 0.05) in the improvement of cough between the two drugs monotherapy group and the higher incidence of cough variant asthma; however, the cough interval time was significantly prolonged in the combination therapy group and cough variant asthma rate Significantly lower than the first two groups (P <0.05). Conclusion The combination of ambroxol and montelukast in children with cough variant asthma can effectively improve the clinical symptoms and is safe and effective.